NEW YORK, March 1 - Aurora Biosciences said Thursday it completed its acquisition of Panvera, a Madison, Wisc.-based manufacturer of recombinant protein drug targets and protein drug screening assays.

Under the terms of the agreement, which has been approved by Panvera shareholders, Aurora will issue up to 1.9 million shares of its common stock in the transaction.

On November 17, the day the deal was originally announced, Aurora’s stock was trading just above $45 a share. Since then, the price has steadily fallen to about $18 a share.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

Technology Review reports that 2017 was the year of consumer genetic testing and that it could spur new analysis companies.

A phylogenetic analysis indicates two venomous Australian spiders are more closely related than thought, the International Business Times reports.

In Science this week: CRISPR-based approach for recording cellular events, and more.

A new company says it will analyze customers' genes to find them a suitable date, though Smithsonian magazine says the science behind it might be shaky.